The environment of the inner ear is highly regulated in a manner that some solutes are
permitted to enter while others are excluded or transported out. Drug therapies targeting the …

Hearing loss is the most common sensory impairment in humans and currently disables 466
million people across the world. Congenital deafness affects at least 1 in 500 newborns, and …

Inner ear gene therapy has recently effectively restored hearing in neonatal mice, but it is
complicated in adulthood by the structural inaccessibility of the cochlea, which is embedded …

Mutations to the OTOF gene are among the most common reasons for auditory neuropathy.
Although cochlear implants are often effective in restoring sound transduction, there are …

Sensorineural hearing loss is associated with gradual degeneration of spiral ganglion
neurons (SGNs), compromising hearing outcomes with cochlear implant use. Combination …

Pathogenic mutations in the OTOF gene cause autosomal recessive hearing loss (DFNB9),
one of the most common forms of auditory neuropathy. There is no biological treatment for …

Cochlear gene therapy holds promise for the treatment of genetic deafness. Assessing its
impact in adult murine models of hearing loss, however, has been hampered by technical …

The development and maintenance of spiral ganglion neurons (SGNs) appears to be
supported by both neural activity and neurotrophins. Removal of this support leads to their …

Aminoglycosides are commonly used antibiotics that often induce ototoxicity leading to
permanent hair cell loss and hearing impairment. The ototoxic effects of aminoglycosides …

The isolated anatomical position and blood-labyrinth barrier hampers systemic drug delivery
to the mammalian inner ear. Intratympanic placement of drugs and permeation via the round …